<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 64 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page63.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=64">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 64 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 64</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=64"><img src="../thumb/64.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.5.4 / 1.6                                            2020-04 / 33
       coma, phaeochromocyt., bone marr.depress., caut.in hypertens., not   Side effects: Hepat.dysfunct.incl.fatal hepat. fail., thrombocytopen.,   0,3 mg/kg every 1-2 wks.until optim.respons.achiev. Usual maint.
       safe in ac.porphyr., safety in pregn. & lactat. not est.  inhibit.of platelet. aggregat., revers. prolongat.of bleed.time, red cell   dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max. dly.dos.of 200 mg
       Side effects: Freq: Akathis., ac.dyston., parkinson.-like syndr., tard.  hypoplas., bld.dyscras.incl.anaem.& bone marr. depress, hyperam-  not to be exceed. If calcul. dly. dos. is 1-2 mg, 2 mg may be taken on
       dyskines., dry mouth, nas. congest., constip., eye pigm.deposit.dur.  monaem., dysmenorrh., galactorrh., gynaecomast., GI disturbs., ac.   altern. days for the first 2 wks. Do not admin.if calc.dos.is less than
       longt. ther., blurr.vis., corn.opacit., postur.hypotens., hypertens. Less   pancreatit., CNS effs. incl.stupor & coma, vertigo, invol.movem., hy-  1 mg. Pts.aged 2-6 yrs.may require maint. dos. at high.end of scale.
       freq: CNS eff., cataton.-like state, EEG chang., convuls., temp.regul.  peractiv., ton.spasms, atax., oed., imp.co-ordinat., trem., asterixis,   Lennox-Gastaut Syndr: Dos.guidelines as above for adults &
       dysfunct., mios., extrapyramid.sympt., NMS, perior.trem., micturit.   dysarthria, hear. loss, nystagmus, diplop., depress., allerg. skin reacts.,   childr.aged 2-12 yrs.
       diffic., photosens., mydrias., card.disords., SLE, skin pigment de-  petech.bleed., haematoma developm., trans.alopec., Reye-like syndr.,  Contraindications: Safety in pregn.& lactat.not est., ren./hepat.
       posit.dur.prolong.ther., jaund., weight gain, reproduct.syst.disords.  Special precautions: Bone marr.abnormal., childr. und.3 yrs.as they   funct.impairm., pts.over 65 yrs.,
       incl.priapism, bld. dyscras., potent.fatal agranulocytos. Unknown   esp.predispos.to hepat. fail., congenit.enzyme defects, haemorrh.   Side effects: Freq: Headache, tiredn., dizzin., drowsin., coordinat.
       freq: Hyperglycaem., alt.gluc.tol., hypersens. reacts.incl.urticar./ex-  diathesis, ment.retard.childr., organ.cerebr.les., ren. dysfunct., sev.  abnormalit., atax., vis. abnormal. incl.blurr.vis.& diplop., N&V. Less
       foll.dermatit./ erythema multiforme/cont.sens.  epilept.seiz types, monit.liv. funct.esp.dur.1st 6 mnths.& dur.upward   freq: Bld. dyscras.incl.anaem./eosinophil./leucopoen./ thrombocyto-
       Warnings and special precautions: Psychot. suicid./tard.dys-  dos. titrat., discont.grad.und.medic.supervis.in pres.of clinic. sympts.  pen., hemophagocyt. lymphohistiocytos., hypersens.syndr., anx, con-
       kines.risk, liv./ren./CV/ cerebrovasc./ resp.impairm., clos.-angl.glauc.,   of hepat.damage/pancreatit., surg. & dent.intervent., monit.platel./  fus., depress., irrit., incr.seiz., nystagmus & insomn., trem., amnes.,
       parkinson., diab.mellit., epilep., hypothyroid., myasth. grav., prostat.  ren.funct., SLE, other concom.anticonvuls., concom.meds.which in-  slurr.speech., angioed., constip., diarrh., dyspeps., asthen., pain. Freq.
       hypertrophy, avoid in untreat. epilep., elderly esp.with dement., de-  terfere with bld.coagulat.  unknown: Agranulocytos., disseminat.intravascul.coagulat., neutro-
       bilit., eff.on vomit.centre poss.mask sympt.of other agents overdos./  Drug interactions: Free lev.of phenytoin, phenobarbit. & diazepam.  pen., red cell aplas., apnoea, oesophagit., multi-organ fail., dry mouth.
       GI obstruct.disords., avoid. admin. dur.extreme temps., reg.eye exam.  incr., metabol.of diazepam. inhibit., primidone ser.lev.incr., ethosux-  Warnings and special precautions: Monother. in childr.und.12
       dur.longt.ther., direct sunl.expos., reg.haematolog.paramet.monit.,   imide eff.potent., phenytoin/phenobarbit. & primidone reduc.plasma   yrs.not recomm., insuffic.info.in childr. und.2 yrs., advis.pts.to seek
       abrupt withdr., lact.intol.   lev., clonazepam may induc. absence status, felbamate incr.plasma   med.attent.if exper. sympts.of hemophagocytic lymphohistiocytosis
       Interactions: Enhanc.CNS depress.eff.with other CNS depress.incl.  lev., eliminat.half-life of lamotrigine incr., naloxone theoretic.may   (HLH), cases of sev.convuls. seiz. incl.stat.epilept.may lead to rhab-
       alcoh./anaesthet., dos.adjustm. with other agents produc.postur.hy-  rev.anti-epilept.effs., salicylates may cause clinic.relev.tox.conc.  domyolys/ multiorg. dysfunct.& disseminat.intravasc. coagulat., close
       potens., antihypertens. eff.of guanethidine & other adrenerg. neur.  esp. childr. of valproic acid, hepatotox.drugs may potent. valproic   monit.of hepat./ren.& clott. paramet., consid.withdr.if unexplain.rash/
       block.poss.reduc., adverse eff.of other antimuscarin.meds.poss.po-  acid.liv.advers.effs., eff.of MAOI potent., eff.of CNS depress.enhanc.  fev./flu-like sympts./drowsin.or worsen.of seiz.contr. occur, abrupt.
       tent.incl.TCA’s/ antimuscar.anti-parkinson.agents, poss.incr. extrap-  DEGRANOL, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  withdr.may provoke rebound seiz., grad. withdr., monit.childr.weight
       yramid. eff.with metoclopramide, incr. ventric. arrhythm.risk with   Carbamazepine.  to maint.ther. dos., to minim.risk of skin rash recomm.dos escalat. not
       halofantrine/anti-arrhythm./antihist./antimalar.agents/cisapride.  Indications: Psychomot./temp.lobe/grand mal/ mix.forms/foc.seiz.  to be exceed., consid.poss.of adv. react. in childr.develop.sympts.of
                                     epileps., trigem.neuralg.    rash & fev.dur. first 8 wks of ther., eval.all pts.prompt.if rash./ early
                                                                  manifestat.of hypersens.occur, grad.transient incr. in lamotrigine
                                     (S3) TABS. G/2.5/220.        lev.& incr.adv.effs.poss.dur. inact. wk.in pts taking OCs that incl.1
       1.6    Anti-epileptics        712493-018: 200 mg, 100, R261,59  wk.of inact. med, investig.any change in menstr.bleed.pattern., poss.
                                     Dosage: Adults: Init.½-1 tabs once or 2xdly follow. by slow incr.
       FYCOMPA (MDR Listing)         unt.best respons.obtain. usual.2 tabs 2 or 3 xdly. 8 tabs.may be giv.  suicide risk with bipolar disord.& close supervis. of high-risk pts.adi-
                                                                  vis., adhere to recomm. dos.esp.if valproate used concom., heredit.
       KEPPRA (MDR Listing)          in 3 -4 div.dos.if necess.   condits.of galact.intol./Lapp lactase defic./gluc.-galact.malabsorpt.
       LAMICTIN (MDR Listing)        Childr: Admin.in sev.fraction.dos.Usual.10 -20 mg/ kg/ day. Up to   Interactions: Enzyme induc.agents enhanc. metabol. lead.to incr.
       LYRICA (MDR Listing)          1 yr: ½ -1 tab.dly. 1-5 yrs: 1-2 tabs dly. 5-10 yrs: 2-3 tabs dly. 10-  clear.& subseq.reduc.elimin. half-life, hormon.contracept.contain.
       NAVALPRO (MDR Listing)        15 yrs: 3-5 tabs dly.        ethinyloestrad. & levonorgestr.incr.clear., effic.of hormon. contracept.
       NAVALPRO CR (MDR Listing)     Trigem.neuralg: Init. 1 tab 2xdly incr.grad.till desir. respon., usu-  poss.decr., concom.valproic acid incr.half-life & plasma conc., plasma
       VALEPTIC (MDR Listing)        ally 1 tab 3-4xdly.          conc.of valproic acid decr., as an inhibit.of dihydrofol. reduct. base
                                     Contra-indications: Pregn.& lactat., liv.dis., heartblock, por-
       BIOTECH GABAPENTIN, Biotech [P/S]  phyr., MAOI’s.          exerc.caut.with other folate antagon.
       Gabapentin.                   Side-effects: Liv.funct.abnorm./ jaund.dur. longt. ther., dry mouth,   DYNA LEVETIRACETAM, Pharma Dynamics [P/S]
       Indications: Adjunct.to other std.anticonvuls. meds. where adeq.  GI disturbs., CNS effs., vis. disturbs., hyponatraem., allerg./skin re-  Levetiracetam
       seiz.contr.has not been achiev. with agents use.alone/in combi-  acts., paraesthes., system.LE, Steven’s-Johnson syndr., photosens.,   Indications: Adjunct.ther.in partial onset seiz. with/without second.
       nat., simple & complex part.seiz. with/without second.gen.tonic-  alter.skin pigment., bld.dyscras., hepatocellul./ cholestat.hepatit.,   generalisat.in adults & childr. over 16 yrs.with epilep.
       clonic seiz.                  ac.oligur.with hypertens., proteinur., CV effs.incl.left ventric. fail./  (S3) TABS, 44/2.5/0368, 0369, 0370, 0371
       (S3) CAPS, 43/2.5/0332, 0329, 0333  card.impulse conduct.disturbs.  718486-001: 250 mg, 60, R119,64
       721740-001: 100 mg, 100, R166,29  Special precautions: Elderly, observe serum folic acid lev.dur.ther.,   718485-001: 500 mg, 60, R239,31
       721741-001: 300 mg, 100, R412,23  freq.bld.counts & liv. funct.test bef.start./dur.treatm., withdr.in pres.  718484-001: 750 mg, 60, R364,66
       721742-001: 400 mg, 100, R412,23  of allerg.reacts./decr.platel.counts/ liv.funct. deterior., CV dis., ren./  Dosage: Admin.dly.dos.in 2 equal div.dos.
       Dosage: May be used as adjunct with phenobarb./ phenytoin/valp-  liv.disords., glauc., toler., eff.transf.to other anti-epilept. und.cover of   Monother: Adults & adolesc.old.than 16 yrs: Therapeut.dos.of
       roic acid/ carbamazepine. Adults & childr.over 12 yrs: Init. 300 mg   diazepam/barbits., pass.into breast milk, outweigh benef.-risk if a   500 mg 2xdly start.on 1  day of treatm. Dly.dos.may be incr.up to 1 500
                                                                            st
       3xdly. incr.grad.accord.to respons. Usual. effect. dos: 900-1 800 mg/  woman becom.pregn.dur.ther. esp. dur.first trimest., oral anticoag.ther.   mg 2xdly. depend.upon clinic.respons.& tol. Dos.changes can be made
       day in 3 div.dos.with not more than than 12 hrs.betw.dos. Dos.up to   Drug interactions: Poss.enhanc.folic acid metab., reduc.alcoh.  in 500 mg 2xdly increm./decrem.every 2-4 wks. Max.dly dos: 3000 mg.
       3 600 mg/ day in 3 div.dos.for short per.have been toler.  toler., dimin.activ.of other anti-epilept.agents/ tetracycl./doxycycl.,   Contraindications: Pyrrolidone derivat. hypersens., pregn., lactat.,
       Contraindications: Safety & effic.in childr.und. 12 yrs. not est.,   aff.OC reliabil.   insuffic data in childr. und.16 yrs.
       safety in pregn. & lactat./porphyr. not est., lact.intol.  Side effects: Infect., bld.dyscras., pancreatit., anorex., psych.disor-
       Side effects: CNS eff.incl.atax., vertigo, paraesthes., nystagm., vis./  DYNA-LAMOTRIGINE, Pharma Dynamics [P/S]  ds.incl.depersonalisat./ depress/hostility & psychot.disords., dizzin.,
       dent.abnormalit.incl. diplop., conjunctivit., psych./urin.disords., dizzin.,   Lamotrigine  headache, somnol., paraesthes., nervousn., trem., diplop., vertigo,
       drowsin., fatig., trem., mouth/throat dryn., dysarthr., headache, trou-  Indications: Adults & childr.over 12 yrs: Monother./ add-on treatm.  GI disturbs., pharyngit., rhinit., sinusit., cough., skin rash, alopec.,
       ble think., vir.infect., leucopen., myalg., asthen., fract., periph.oed., GI   of part .epilepsy with/ without second.general.ton.-clon.seiz., & in   atax., asthen., accid.injury,
       disturbs., hypotens., vasodilat., chest pain, palpitat., rhinit., pharyngit.,   prim. gen. ton.-clon.seiz. Childr. 2-12 yrs: Add-on treatm. of part.  Special precautions: Grad.withdr./tfd.to other anti-epilept.ther.,
       cough., RTI, tinnit., otit. med., weight gain, skin reacts.incl.erythema   epilep.with/without second gen.ton.-clon. seiz. not satisfact.con-  ren.impairm.esp.elderly, monit. ren. funct.in sev.imp.hepat.funct.,
       multiforme/Stev.Johns. syndr., impot., pancreatit.  trol.with other anti-epilept. meds., add-on treatm.for seiz.assoc.
       Special precautions: Monit.for emerg./worsen. of depress./suic.  with Lennox-Gastaut Syndr.  EPANUTIN, Pfizer [P/S]
       ideat.or mood/behav.chang., admin. at least 2 hrs.aft.antacid, withdr./  (S3) TABS, A40/2.5/0173, 0169, 0166, 0167  Phenytoin Na
       addit.of anoth. agent to be grad., diab.mellit., psychot.illn. hist., ren.   710387-001: 25 mg, 60, R104,45  Indications: Gen.tonic-clonic (grand mal) & complex part. (psycho-
       impairm., poss.status epilept.with abrupt withdr., discont.grad., elderly.  710388-001: 50 mg, 60, R152,39  mot., tempor.lobe) seiz.
       Drug interactions: CNS depress.effs.incr.by CNS depress. & alcoh.,   710389-001: 100 mg, 60, R250,20  (S3) CAPS, [P/S] B554.
       Mg & Al contain.antacids reduc. bioavail.  710390-001: 200 mg, 60, R403,32  723525-005: 100 mg, 100, R297,48
                                     Dosage: Do not exceed max.recomm.dos.esp.in combinat.with val-
                                                                  Dosage: Individ. Optim.contr.often achiev.with ser. lev. betw. 10-
       CONVULEX, Takeda [P/S]        proate. If calcul.dos.,esp.in childr. does not equate to whole tab.admin.  20 mcg/ml although mild tonic-clonic epilep.posib.contr.at low ser.
       Valproic acid.                dos.as equal to low.no.of whole tabs. Use dos.escalat. recomm. for   lev., 7-10 day period recomm.to achiev.steady state & dos.chang.
       Indications: Gen.seiz., part.(focal) seiz, ac.man. episod.assoc.with   concom.valproate in pts.taking antiepilept. drugs where pharmacoki-  should not be carr.out at shorter interv. Adults: Init.100 mg 3xdly
       bipol.disords.when intol/ unsatisfact.respons.to Li, migr.prophylax.  net.interacts. current. unknown.  then indiv.with satisfact. maint. dos.betw. 300-400 mg dly.taken in
       when other meds.don’t have desir.eff.  Monother: Adults & childr.over 12 yrs: Init. 25 mg once dly.x2   3-4 equal. div.dos., Max. 600 mg dly. Non emerg.oral load.dos.(re-
       (S3) CAPS, [P/S] R/2.5/218,219, W/2.5/20.  wks., follow.by 50 mg once dly. x2 wks. Thereaft.dos.may be incr.  serv.for clinic/hosp.setting where ser. lev. monit.poss.): 1 g div.in 3
       715980-009: 150 mg, 100, R361,88  by max.50-100 mg every 1-2 wks.until optim.respons.achiev. Usual   equal dos.of 400 mg, 300 mg & 300 mg admin.at 2 hr.interv. Norm.
       715999-001: 300 mg, 100, R628,34  maint.dose: 100-200 mg/day admin.once dly or in 2 div.dos., 500 mg/  maint. dos.comm.24 hrs.later. Dly dos.of 300 mg may be consid.if
       781568-005: 500 mg, 100, R930,88  day may be req.by some pts.  control est.with div.dos.
       (S3) SYRUP, [P/S] W/2.5/390. 50 mg/ml.  Add-on ther: Adults & childr.over 12 yrs. With enzyme induc   Paed.dos: Init. 5 mg/kg/day in 2-3 div.dos.with subseq.dos.individ.to
       Sod.valproate.                anticonvuls.only: Init: 50 mg once dly x 2 wks.follow.by 100 mg/  max.of 300 mg dly. Recomm. maint.dos.range 4-8 mg/kg/day. Childr.
       781541-018: 100 ml, R134,80   day in 2 div.dos.x2 wks. thereaft. dos.may be incr.by max. 100 mg   over 6 yrs. may req.min.adult dos.300 mg/day. If dly.dos. cannot be
       Dosage: Admin.tot.dly.dos.in div.dos.  every 1-2 wks. until optim.respons.achiev. Usual.maint. dos: 200-  div.equal.admin.larger dos.at bedt.
       Epilepsy: Adults: Init: 600 mg/day in div.doses, incr.by 150 mg/day   400 mg/day in 2 div.dos.  (S3) FORTE SUSP, [P/S] B555. 125 mg/5 ml.
       to maint.dose of 1 000-1 600 mg/day. Max: 2 600 mg/day. Childr.less   With enzyme induc anticonvuls.& valproic acid: Init: 25 mg every al-  Phenytoin (free acid form)
       than 20 kg: 15-20 mg/kg/day, in sev.cases dos.can be incr.at 1 wk.in-  tern.day x2 wks., follow by 25 mg once dly.x2 wks.thereaft.dly.dos.  723533-016: 237 ml, R329,44
       terv.by 5-10 mg/kg/ day.to 40 mg/ kg/day. More than 20 kg: 450 mg   may be incr. by max. 25-50 mg/day every 1-2 wks.until optim. respons.  Dosage: Individ. Optim.contr.often achiev.with ser. lev. betw. 10-
       dly.in div.dos., incr. grad.to est.control at usual. 20-30 mg/kg/day.  achiev. Usual maint.dos.to achieve optim. respons: 100-200 mg/ day   20 mcg/ml. 7-10 day period recomm.to achiev. steady state. & dos.
       Ac.mania in bipol affect.disords: Init: 600-900 mg/day in div.dos.   giv.once a day/in 2 div. dos.  chang. should not be carr.out at shorter interv. Adults: Init. 125 mg
       High.aggitat.pts: Up to 1 500 mg/day. Grad.dos.incr.at 2-4 day interv.   Childr. 2-12 yrs: Pts.not tak.sod.valproate: Init. 0,6 mg/kg bm/day in   3xdly then indiv. Non-emerg.oral load. dos.(reserv.for clinic/hosp.set-
       with plasma lev.monit.        2 div. dos.x2 wks., follow.by 1,2 mg/kg/day x2 wks. Thereaft.the dos.  ting where ser.lev. monit.poss.): 1 g in 3 div.dos.(400 mg-300 mg-300
       Migraine: Adults only: Init.300 mg/day in div. dos. incr.dly.dos.  should be incr. by a max.1,2 mg/kg every 1-2 wks.until optim. respons.   mg) admin.at 2 hr.interv. Instit.norm.maint.dos.24 hrs. aft.load.dos. Dly
       grad.until.desir.respons./advers. effs. Usually 600-900 mg/day with   achiev. Usual maint.dos.to achieve optim. respons: 5-15 mg/kg/day in   dos.of 300 mg may be consid. if control est.with div.dos
       plasma lev. monit.            2 div.dos. Max.dly. dos. of 400 mg not to be exceed.  Paed.dos: Init. 5 mg/kg/day in 2-3 div.dos.with subseq.dos.individ.
       Contraindications: Hepat.& pancreat. dysfunct., teratogenic. as-  Childr.tak.sod.valproate: Init: 0,15 mg/kg bm/day once dly x 2wks.fol-  to max.of 300 mg dly. Recomm. dly.maint.dos. 4-8 mg/kg. Childr.over
       soc.in pregn.                 low.by 0,3 mg/kg/day giv.once a day x2 wks. Thereaft.incr.dos by max.   6 yrs.may req. min.adult dos.300 mg/day.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page63.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page59.html">59</a>&nbsp;&nbsp;&nbsp;<a href="page60.html">60</a>&nbsp;&nbsp;&nbsp;<a href="page61.html">61</a>&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>
             </td>
             <td width="35%"><a href="page65.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page65.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
